Alternative splicing (AS) of pre-mRNA plays a crucial role in tissue-specific gene regulation, with disease implications due to splicing defects. Predicting and manipulating AS can therefore uncover ...

The discovery could pave the way for a groundbreaking RNA-based multi-cancer treatment. Alternative RNA splicing functions ...

Dyne Therapeutics’ DYNE-101 shows positive results in phase 1/2 ACHIEVE study. Read why DYN stock may rise with FDA approval and a $2.78B market opportunity.

Natural "off switch" could slow or even reverse the growth of aggressive tumors.

Emerging evidence suggests that some variants, which are described as missense, synonymous or nonsense variants in the literature or databases, may be deleterious by affecting the pre-mRNA splicing ...

A study reveals how cancer disrupts RNA splicing and presents a potential therapy using antisense oligonucleotides to target ...

This study shows that RNA decay rather than the presence of premature termination codons triggers a TA-like response.